Treatment with a bispecific GPA33–CD3 monoclonal antibody (MGD007), recruiting human T-cells, induced lysis of GPA33 expressing CRC cells and reduced tumor growth in vivo in NOD/SCID mice subcutaneously injected with a 1:1 mixture of colorectal cancer cell lines (LS174T and Colo205) with purified T-cells (72). This evidence concerns the gene GPA33 and colorectal cancer.